Tuesday, 16 April 2024


Korea's Samsung Bioepis inks immunology biosimilar deal with Sandoz

12 September 2023 | News

For commercialisation rights to biosimilar SB17 ustekinumab in Europe and North America

Image credit: shutterstock

Image credit: shutterstock

Sandoz, a division of Swiss firm Novartis in generic and biosimilar medicine, has entered into a development and commercialisation agreement with Korean firm Samsung Bioepis.

The agreement provides Sandoz with the exclusive rights to commercialise the biosimilar SB17 ustekinumab in the US, Canada, European Economic Area (EEA), Switzerland, and UK. 

The reference medicine Stelara (ustekinumab) is a monoclonal antibody medication to interleukin (IL)-12/23 for the treatment of autoimmune disorders including Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.

SB17, a proposed biosimilar to Stelara (ustekinumab), is Samsung Bioepis’ fourth candidate in its immunology pipeline, following SB4 (etanercept), SB2 (infliximab) and SB5 (adalimumab). Samsung Bioepis has a more than 5-year track record of supplying over 48 million units of immunology biosimilars in nearly 40 markets across the world.

The partnership's primary objective is to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account